Core Viewpoint - Alvotech and Dr. Reddy's Laboratories have entered a collaboration to co-develop a biosimilar candidate to Keytruda® (pembrolizumab), which had worldwide sales of US$29.5 billion in 2024, aiming to enhance the availability of cost-effective biologic medications for cancer treatment globally [1][2][3][4]. Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, with a goal to be a leader in the biosimilar space by providing high-quality, cost-effective products [7]. - Dr. Reddy's Laboratories is a global pharmaceutical company committed to providing access to affordable and innovative medicines, with a focus on various therapeutic areas including oncology [10][11]. Collaboration Details - The collaboration agreement stipulates that both companies will share responsibilities and costs in the development and manufacturing of the biosimilar candidate, with each party having the right to commercialize the product globally [2]. - This partnership is expected to leverage the strengths of both companies in biosimilars, accelerating the development process and expanding market reach [1][3][4]. Market Context - Keytruda® is a critical therapy in immuno-oncology, and the collaboration aims to enhance the capabilities of both companies in this therapeutic area [4]. - The biosimilars market is growing, and this collaboration positions both companies to capitalize on the increasing demand for affordable cancer treatments [3][4].

Core Viewpoint - Alvotech has successfully completed a private placement of 7,500,000 shares, raising gross proceeds of SEK 750 million, with strong interest from institutional investors, particularly from Sweden and other international markets [2][4][5]. Group 1: Placement Details - The private placement included 5,833,500 Swedish Depository Receipts (SDRs) and 1,666,500 ordinary shares, priced at SEK 100.00 per SDR and ISK 1320.83 per ordinary share, reflecting current market conditions [3][5]. - The transaction was facilitated by DNB Carnegie and Citi as Joint Global Coordinators and Joint Bookrunners, with SEB and ACRO also participating as Joint Bookrunners [2][3][13]. - Settlement of the placement is expected around June 10, 2025, for both SDRs and ordinary shares [8]. Group 2: Use of Proceeds - The net proceeds from the placement will be allocated to upscale R&D efforts, particularly in Sweden, following the acquisition of Xbrane's R&D operations, and to capitalize on growth opportunities [5][7]. - The funds will also be used for general corporate purposes, enhancing the company's market position [5]. Group 3: Shareholder Base and Market Impact - The placement is expected to diversify and strengthen Alvotech's shareholder base, particularly among institutional investors in Sweden, and significantly increase the float of SDRs on Nasdaq Stockholm [7]. - The strong interest from institutional investors indicates the importance of the SDR listing on Nasdaq Stockholm for the company's growth strategy [4][7].

Core Viewpoint - Alvotech intends to conduct a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares to strengthen its shareholder base and fund R&D activities [2][4]. Group 1: Placement Details - The placement will be executed through an accelerated bookbuilding procedure, with pricing and total number of SDRs and ordinary shares to be determined during this process [3][6]. - The completion of the bookbuilding and pricing is expected before trading starts on Nasdaq Stockholm at 09:00 CEST on June 5, 2025 [3]. - The company may adjust the timing of the bookbuilding and has the discretion to shorten, extend, or suspend the placement [3]. Group 2: Use of Proceeds - Net proceeds from the placement are intended to accelerate Alvotech's R&D activities, particularly following the acquisition of Xbrane's R&D operations [4]. - The funds will also be used for general corporate purposes, allowing Alvotech to expand its pipeline and capitalize on growth opportunities [4]. Group 3: Shareholder and Management Commitments - The company and its executive management have agreed not to sell or transfer additional SDRs or ordinary shares for 180 days post-placement settlement, subject to certain conditions [7][8]. - Major shareholders have also committed to not dispose of their holdings for 90 days following the placement [10]. Group 4: Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, with two biosimilars already approved and a pipeline of nine candidates targeting various diseases [13]. - The company aims to be a global leader in the biosimilar market, leveraging strategic partnerships for market reach [13].

Core Viewpoint - Alvotech has successfully completed the acquisition of Xbrane Biopharma's R&D organization and a biosimilar candidate to Cimzia®, enhancing its development capacity and presence in the Swedish life science sector [1][2]. Group 1: Transaction Details - The acquisition was announced on March 20, 2025, and approved on April 14, 2025, with a total purchase price of approximately SEK 275 million (US$28.9 million) [2]. - The payment structure includes a cash payment of approximately SEK 102.2 million, assumption of convertible debt of approximately SEK 152.75 million, and assumption of accounts payable related to the biosimilar candidate of approximately SEK 20 million [7]. Group 2: Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space with a fully integrated approach and broad in-house capabilities [4]. - The company has two approved biosimilars, targeting Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates for various diseases [4]. - Alvotech has established strategic commercial partnerships across multiple regions, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [4].

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3] Upcoming Events - Alvotech will participate in the Jefferies Global Healthcare Conference 2025 in New York from June 3-5, 2025 [1] - Dr. Balaji Prasad, Chief Strategy Officer, will present recent business updates on June 5, 2025, from 10:30 am to 11:00 am EDT [1] - A live video webcast of the presentation will be available to the public, with a recording accessible for 90 days post-event [2]

Core Insights - Alvotech and Advanz Pharma have expanded their commercial partnership to include three additional biosimilar candidates, enhancing their collaboration in the European market [1][2][8] Group 1: Partnership Details - The new agreement includes biosimilar candidates to Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed candidate, with Alvotech responsible for development and supply, while Advanz Pharma handles registration and commercialization in Europe [2][4] - The agreement encompasses development and commercial milestones totaling up to US$180 million (EUR 160 million) and includes a revenue-sharing model between the partners [2][4] Group 2: Market Potential - The partnership now covers proposed biosimilars referencing over ten originator biologics, with the current addressable market for these products in the relevant countries estimated at least US$13.8 billion [5][3] - Advanz Pharma aims to broaden access to rare disease and specialty medicines through this expanded collaboration, reinforcing its growth strategy in the biosimilars sector [4][3] Group 3: Company Background - Alvotech is focused on developing and manufacturing biosimilar medicines, with a pipeline that includes eight disclosed candidates targeting various diseases, including autoimmune disorders and cancer [7] - Advanz Pharma operates globally, with a focus on specialty, hospital, and rare disease medicines, and has a commercial presence in over 90 countries [10]

Group 1 - The Annual General Meeting (AGM) of Alvotech is scheduled for June 25, 2025, at 09:00 a.m. CEST [1] - The meeting will take place at the premises of Arendt & Medernach in Luxembourg [1] - Additional information and meeting materials are available on the Alvotech website [1]

Group 1: Company Overview - Alvotech is a biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services [3] - Alvotech has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), marketed in multiple global markets [3] - The current development pipeline includes nine disclosed biosimilar candidates targeting various diseases, including autoimmune disorders and cancer [3] Group 2: Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise [3] - Key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co., Ltd., among others, covering various territories [3] - Each partnership is tailored to specific products and regions, enhancing Alvotech's market presence [3] Group 3: Liquidity Provider Agreement - Alvotech has entered into an agreement with DNB Carnegie Investment Bank AB for liquidity provider services for its Swedish Depository Receipts (SDRs) [1] - DNB Carnegie will continuously quote prices for Alvotech's SDRs to ensure liquidity and reduce the spread between buying and selling prices [2] - The liquidity provider arrangement is set to commence on May 20, 2025 [2]

Core Viewpoint - Alvotech has successfully completed its offering of Swedish Depository Receipts (SDRs) and is now listed on Nasdaq Stockholm, which is expected to enhance its visibility and access to capital in the Nordic and European markets [2][4][6]. Offering Details - The offering was oversubscribed multiple times, with a total of 441,600 SDRs issued at a price of SEK 87.51, resulting in gross proceeds of approximately SEK 39 million [8]. - The application period for the offering was from May 9 to May 16, 2025, and trading commenced on May 19, 2025, under the ticker "ALVO SDB" [8]. Strategic Expansion - Alvotech aims to expand its R&D capabilities by acquiring Xbrane Biopharma AB's R&D operations in Sweden, which will enhance its scientific and innovation capabilities [5]. - The integration of Xbrane's workforce is expected to strengthen Alvotech's presence in the Swedish life-science sector and support its growth trajectory [5]. Market Positioning - The listing on Nasdaq Stockholm is anticipated to improve access to regional capital and attract a broader base of institutional and retail investors [6]. - Alvotech is focused on becoming a global leader in biosimilars, with a current pipeline that includes nine disclosed biosimilar candidates targeting various diseases [11]. Shareholder Engagement - The company will offer a free conversion period for existing shareholders to convert their shares into SDRs, with Alvotech covering the conversion fees for one year [9].

Core Viewpoint - Alvotech, a global biotech company focused on biosimilar medicines, successfully completed an oversubscribed offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm, which is expected to enhance its market presence and access to capital [2][5][8]. Offering Details - The offering attracted strong interest, resulting in over 3,000 new shareholders and was multiple times oversubscribed [2][8]. - The final price per SDR was set at SEK 87.51, reflecting a 10% discount from the volume-weighted average price of the ordinary shares during the application period [8]. - The gross proceeds from the offering amounted to approximately SEK 39 million [8]. Strategic Expansion - Alvotech aims to expand its R&D capabilities, having recently acquired Xbrane Biopharma AB's R&D operations in Sweden, which will enhance its scientific and innovation capabilities [4]. - The integration of Xbrane's workforce is expected to strengthen Alvotech's presence in the Swedish life-science sector and support its growth trajectory [4]. Market Positioning - The listing on Nasdaq Stockholm is anticipated to improve Alvotech's recognition in Nordic and European markets, attracting a broader base of institutional and retail investors [5]. - There is strong investor demand for opportunities in European biotech, biopharma, and biosimilar stocks among Nordic and international institutional investors [5]. Trading Information - Trading of the SDRs on Nasdaq Stockholm is set to commence on May 19, 2025, under the ticker symbol "ALVO SDB" [8]. - A free conversion period for existing shareholders to convert their shares into SDRs will be offered for one year from the first trading day [7].